CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

CVS Health (CVS) is maintaining Thursday gains ahead of the closing bell after outpacing top and bottom line expectations, ...

CVS Caremark announced a partnership with Novo Nordisk (NYSE:NVO) to expand access to Wegovy, a GLP-1 drug for obesity, at a ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Hims & Hers Health (NYSE:HIMS) recently announced a partnership with Novo Nordisk to enhance obesity care access in the U.S., coinciding with a notable 24% increase in its stock price over the last ...